Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Particle Clear all
Completed Phase 1 Interventional

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose

NCT01257191
View directory record Official record
Conditions
Hypersensitivity, Immediate, Atopic Hypersensitivity
Interventions
Carbon Black, Diesel Exhaust Particles, Fine Concentrated Ambient Particles, Ultrafine Concentrated Ambient Particles, Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 6:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

NCT03330197
View directory record Official record
Conditions
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions
Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
0 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 23, 2026, 6:25 AM EDT
Active, not recruiting Not applicable Interventional

CTSN Embolic Protection Trial

NCT06027788
View directory record Official record
Conditions
Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Interventions
CardioGard Embolic Protection Cannula, Standard Aortic Cannula
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

NCT00517543
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Prolonged Fasting on Microbiome and HDL

NCT03487679
View directory record Official record
Conditions
Fasting
Interventions
Fasting
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 23, 2026, 6:25 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
Drug
Lead sponsor
Seattle Project Corporation
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Use of Fenofibrate for Primary Biliary Cirrhosis

NCT00575042
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 23, 2026, 6:25 AM EDT
Recruiting Early Phase 1 Interventional

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

NCT05893186
View directory record Official record
Conditions
Parkinson Disease
Interventions
Deep Brain Stimulation, STN, GP Deep Brain Stimulation
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Not applicable Interventional Results available

Aerosol Particle Concentrations Among Different Oxygen Devices for Spontaneous Breathing Patients With Tracheostomy

NCT04654754
View directory record Official record
Conditions
Transmission, Patient-Professional
Interventions
high-flow high humidity oxygen device with tracheostomy adapter
Device
Lead sponsor
Jie Li
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 23, 2026, 6:25 AM EDT
Terminated Phase 2 Interventional Results available

Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise

NCT04427566
View directory record Official record
Conditions
COVID-19
Interventions
Radiation therapy
Radiation
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

NCT02588326
View directory record Official record
Conditions
Hypersensitivity
Interventions
Mometasone furoate drug formulation (MFF) 1, Mometasone furoate drug formulation (MFF) 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 23, 2026, 6:25 AM EDT
Recruiting Not applicable Interventional

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

NCT06778447
View directory record Official record
Conditions
Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
Interventions
VIA Disc NP, Sham
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Napa, California • Santa Monica, California • Thornton, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Terminated Phase 2 Interventional Results available

Prevention of Restenosis Following Revascularization

NCT00518284
View directory record Official record
Conditions
Vascular Disease, Peripheral
Interventions
Nanoparticle Paclitaxel
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Sacramento, California • Gainsville, Florida • Davenport, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 23, 2026, 6:25 AM EDT
Terminated Early Phase 1 Interventional

Breast-Sparing Proton Therapy for Hodgkin's Disease

NCT02070393
View directory record Official record
Conditions
Hodgkins Disease
Interventions
Proton
Radiation
Lead sponsor
Indiana University
Other
Eligibility
10 Years to 30 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 23, 2026, 6:25 AM EDT
Recruiting Phase 3 Interventional

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

NCT06625034
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Not listed Not applicable Interventional

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

NCT05201287
View directory record Official record
Conditions
Degenerative Disc Disease, Low Back Pain, Disc Degeneration
Interventions
VIA Disc NP
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Larkspur, California • Santa Monica, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 23, 2026, 6:25 AM EDT
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

NCT01844323
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 23, 2026, 6:25 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT04190446
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 6:25 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 23, 2026, 6:25 AM EDT